How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?

Clinical Transplantation

Volumn 12, Issue 5, 1998, Pages 379-390

  Gaspari, Flavio ^a   Perico, Norberto ^a   Pisoni, Roberto ^a   Anedda, Maria Franca ^a   Signorini, Orietta ^a   Caruso, Raffaele ^a   Gotti, Eliana ^a   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

Cyclosporine; Kidney transplantation; Pharmacokinetics; Renal function

Indexed keywords

CYCLOSPORIN A;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MICROEMULSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EMULSIONS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; RENAL PLASMA FLOW;

EID: 0031719776     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. KAHAN BD. Cyclosporine. N Engl J Med 1989: 321: 1725.
2. THE CANADIAN MULTICENTRE TRANSPLANT STUDY GROUP. A randomized clinical trial of cyclosporine in cadaveric renal transplantation: analysis at three years. N Engl J Med 1986: 314: 1219.
3. STARZL TE, KLINTMALM GBG, PORTER KA, IWATSUKI S, SCHROTER GPJ. Liver transplantation with use of cyclosporin A and prednisone. N Engl J Med 1981: 305: 266.
4. MACOVIAK JA, OYER PE, STINSON EB, JAMIESON SW, BALDWIN JC, SHUMWAY NE. Four-year experience with cyclosporine for heart and heart-lung transplantation. Transplant Proc 1985: 17 (suppl 2): 97.
5. TRAEGER J, DUBERNARD J, POZZA G. Influence of immunosuppressive therapy on the endocrine function of segmental pancreatic allografts. Transplant Proc 1983: 15: 1326.
6. LINDHOLM A, KAHAN BD. The use of cyclosporine in organ transplantation. In: BACH J-F, ed. T-Cell-Directed Immunointervention. London: Blackwell Scientific, 1993: 77.
7. HOLT DW, JOHNSTON A. Pharmacokinetics and monitoring of cyclosporine A. In: THOMSON AW, STARZL TE, eds. Immunosuppressive Drug Developments in Anti-Rejection Therapy. London: Edward Arnold, 1994: 37.
8. MUELLER EA, KOVARIK JM, VAN BREE JB, GREVEL J, LUCKER PW, KUTZ K. Influence of a fat reach meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 1994: 11: 151.
9. TRULL AK, TAN KKC, TAN L, ALEXANDER GJ, JAMIESON NV. Absorption of Cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. Br J Clin Pharmacol 1995: 39: 627.
10. WINKLER M, RINGE B, OLDHAFER K, KATTNER A, FARBER L, MAIBUCHER A. Influence of bile on cyclosporine absorption from microemulsion formulation in primary liver transplant. Transplant Int 1995: 8: 324.
11. SALVOLDI S, KAHAN BD. Relationship of cyclosporine pharmacokinetic parameters to clinical events in human renal transplantation. Transplant Proc 1986: 18: 120.
12. KASISKE BL, HEIM-DUTHOY K, VENKATESWARA ROA K, AWNI WM. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplantation. Transplantation 1988: 46: 716.
13. KAHAN BD, GREVEL J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988: 46: 631.
14. KEOWN PA, STILLER CR, ULAN RA. Immunological and pharmacological monitoring in the clinical use of cyclosporine A. Lancet 1981: 1: 686.
15. MYERS BD. Cyclosporine nephrotoxicity. Kidney Int 1986: 30: 964.
16. REMUZZI G, PERICO N. Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int 1995: 48 (suppl 52): 70.
17. LINDHOLM AS, KAHAN BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993: 54: 205.
18. KAHAN BD, SHAW LM, HOLT DW, GREVEL J, JOHNSTON A. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem 1990: 36: 1510.
19. GREVEL J, WELSH MS, KAHAN BD. Cyclosporine monitoring in renal transplantation: area under the curve is superior to trough level monitoring. Ther Drug Monit 1989: 11: 246.
20. GASPARI F, RUGGENENTI P, TORRE L, BERTOCCHI C, REMUTZZI G, PERICO N. Failure to predict cyclosporine area under the curve using a limited sampling strategy. Kidney Int 1993: 44: 436.
21. HOLT DW, MUELLER EA, KOVARIK JM, VAN BREE JB, KUTZ K. The pharmacokinetics of Sandimmune Neoral: a new oral formulation of cyclosporine. Transplant Proc 1994: 25: 2935.
22. MUELLER EA, KOVARIK JM, VAN BREE JB, LISON AE, KUTZ K. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients - a concentration-controlled comparison with the commercial formulation. Transplantation 1994: 57: 1178.
23. KAHAN BD, DUNN J, FITTS C, VAN BUREN D, WOMBOLT D, POLLAK R, CARSON R, ALEXANDER JW, CHOC M, WONG R, HWANG DS. Reduced inter- and intra-subject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995: 59: 505.
24. BARONE G, MARTIN BUNKE VC, CHOC MG. The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. Transplantation 1996: 61: 968.
25. KAHAN BD, DUNN J, FITTS C. The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant patients. In: KAHAN BD, ed. Cyclosporine, The Ten-Year Experience. Norwalk, CT: Appleton and Lange, 1994: 2940.
26. KOVARIK JM, MUELLER EA, VAN BREE JB. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - a multicenter investigation in kidney transplant patients. Transplantation 1994: 58: 658.
27. GASPARI F, PERICO N, RUGGENENTI P, MOSCONI L, AMUCHASTEGUI CS, GUERINI E. DAINA E, REMUZZI G. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 1995: 6: 257.
28. MINETTI EE, Cozzi MG, BIELLA E, NAPOLI F, GUIDI E. Evaluation of a short protocol for determination of paraaminohippurate and inulin plasma clearances. J Nephrol 1994: 7: 342.
29. GASPARI F, ANEDDA MF, SIGNORINI O, REMUZZI G, PERICO N. Prediction of cyclosporine area under the curve, using a three-point sampling strategy after Neoral administration. J Am Soc Nephrol 1997: 8: 647.
30. KEOWN P, LANDSBERG D, HALLORAN P, SHOKER A, RUSH D, JEFFERY J, RUSSEL D, STILLER C, MUIRHEAD N, COLE E, PAUL L, ZALTZMAN J, LOERTSCHER R, DALOZE P, DANDAVINO R, BOUCHER A, HANDA P, LAWEN J, BELITSKY P, PARFREY P. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Transplantation 1996: 62: 1744.
31. BRÖCHNER-MORTENSEN J. A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 1972: 30: 271.
32. KAHAN BD, WELSH M, SCHOENBERG L, RUTZKY LP, MATZ SM, URBAUER DL, VAN BUREN CT. Variable oral absorption of cyclosporine. Transplantation 1996: 62: 599.
33. PAUL LC, BENEDIKTSSON H. Chronic transplant rejection: magnitude of the problem and pathogenic mechanisms. Transplant Rev 1993: 7: 96.
34. LINDHOLM AS, HENRICSSON S, DAHLQUIST R. The effect of food and bile acid administration on the relative availability of cyclosporine. Br J Clin Pharmacol 1990: 28: 541.
35. LEVY G, GRANT D. Potential for CsA-Neoral in organ trasplantation. In: KAHAN BD, ed. Cyclosporine, The Ten-Year Experience. Norwalk, CT: Appleton and Lange, 1994: 2932.
36. MIKHAIL G, EADON H, LEAVER N, YACOUB M. Use of Neoral in heart trasplant recipients. In: KAHAN BD. ed. Cyclosporine, The Ten-Year Experience. Norwalk, CT: Appleton and Lange, 1994: 2985.
37. KOVARIK JM, MUELLER EA, VAN BREE JB, TETZLOFF W, KUTZ K. Reduced inter- and intra-individual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994: 83: 444.
38. KOVARIK JM, MUELLER EA, VAN BREE JB. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994: 16: 232.
39. WILCZEK HE, BERGLIN E, BLOHMÉ I, BÄCKMAN L, FEHRMAN I, KÄLLEN R, NYBERG G, SÄWE J, WAHLBERG J. The Swedish nationwide experience of converting transplant patients with Sandimmun to the new galenic formulation Sandimmune-Neoral. Transplant Proc 1997: 29: 280.
40. KAHAN BD. Overview: individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 1985: 40: 457.
41. PERICO N, RUGGENENTI P, GASPARI F, MOSCONI L, BENIGNI A, AMUCHASTEGUI CS, GASPARINI F, REMUZZI G. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 1992: 54: 56.
42. STEINMULLER D, DOUGHERTY J, COUTEE J, SUREK D, SWIES G, LEWIS R. Effect of conversion from Sandimmune to Neoral on glomerular filtration rate in stable renal transplant recipients. Transplant Proc 1997: 29: 298.
43. HOLT DW, MUELLER EA, KOVARIK JM. The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. In: KAHAN BD, ed. Cyclosporine, The Ten-Year Experience. Norwalk, CT: Appleton and Lange, 1994: 2940.
44. AMANTE AJ, KAHAN BD. Abbreviated area under the curve strategy for monitoring cyclosporine microemulsion therapy in immediate post-transplant period. Clin Chem 1996: 42: 1294.
45. JOHNSTON A, KOVARIK JM, MUELLER EA, HOLT DW. Predicting patients' exposure to cyclosporin. Transplant Int 1996: 9 (Suppl 1): 305.